Report Overview

The Canadian Hematology market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Hematology describes a branch of medicine, which deals with the study of blood and its diseases. It is a subspecialty of internal medicine and is concerned with nature, function, and blood diseases. Hematology uses highly developed technology to make specific diagnoses and treat illnesses occurring in all organ systems. It comprises problems related to the red blood cells, white blood cells, platelet, lymph, and bone marrow. Bleeding disorders such as hemophilia, blood cancer, blood clots are some types of blood conditions. About 300,000 Canadians carry an inherited bleeding disorder gene. 1 in 10 of these people (i.e., at least 30,000 Canadians) have symptoms acute enough to require medical care. Many of them have not been adequately diagnosed. Only 10,000 people with inherited bleeding disorders are registered in the Canadian network of inherited bleeding disorder comprehensive care clinics.



Market Drivers

Blood disorders became a critical health issue in Canada, with different causes related to high mortality. Blood disorders, like anemia, blood cancer, hemorrhagic conditions, and blood infections, affect many people annually across all age groups. The rising number of blood donation camps worldwide is a significant factor propelling the hematology market's demand. Increasing incidences of chronic diseases, geriatric population are accelerating the need of the market. The growing prevalence for point-of-care testing devices, improving support from the government through investments, people's interests in cost-effective diagnosis procedures are boosting the development of the market.